Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Spark Therapeutics, Inc.

< Previous 1 2 3 4 Next >
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
Tickers RHHBY
From GlobeNewswire News Releases
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
Tickers RHHBY
From GlobeNewswire News Releases
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
Tickers RHHBY
From GlobeNewswire News Releases
Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer
Tickers RHHBY
From GlobeNewswire News Releases
Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer
Tickers RHHBY
From GlobeNewswire News Releases
Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Tickers RHHBY
From GlobeNewswire News Releases
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
Tickers RHHBY
From GlobeNewswire News Releases
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine
From GlobeNewswire News Releases
Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product
Tickers ONCE
From GlobeNewswire News Releases
Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference
The Science Fair™ aims to engage and educate patients, families and caregivers affected by bleeding 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Enters into Definitive Merger Agreement with Roche
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 19,... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the presentation of preclinical data... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated preliminary data on the... 
Tickers ONCE
From GlobeNewswire News Releases
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the European Commission has... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Nov. 6,... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced findings from three post-hoc... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the launch of Eye Want 2 Know, a... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease today announced that the Committee for Medicinal... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has been named one of Philadelphia’s... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Aug. 7, 2018, at 8:30... 
Tickers ONCE
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (NYSE:PFE), today announced that, with a cumulative... 
Tickers ONCE PFE
From GlobeNewswire News Releases
Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
Achieved historic milestone with first patients treated with LUXTURNA™ (voretigene neparvovec-rzyl) 
Tickers ONCE
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.